Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-09-2308
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)


Related search